

Electronic Supplementary Information

Readily functionalizable phosphonium-tagged fluorescent coumarins for enhanced detection of bioconjugates by mass spectrometry

Antoine Lizzul-Jurse, Laetitia Bailly, Marie Hubert-Roux, Carlos Afonso, Pierre-Yves Renard, Cyrille Sabot*

Normandie Univ, COBRA, UMR 6014 & FR 3038; Univ Rouen; INSA Rouen; CNRS, 1 rue Tesnière 76821 Mont-Saint-Aignan, Cedex (France).
E-mail : cyrille.sabot@univ-rouen.fr


Table of contents

1) Copies of ^1H NMR, ^{13}C NMR spectra.....	2
2) RP-HPLC elution profiles.....	24
3) Spectroscopic data	33
1) Absorption, excitation, emission spectra of coumarin derivatives	33
2) Absorption of the quencher, emission of coumarins 2 and 7 spectra superimposition.....	37
3) Quenching efficiency and fluorescence exaltation of probes 19 and 20 after BACE-1 hydrolysis	38
4) Quenching efficiency and fluorescence exaltation of probes 19 and 20 after α -Chymotrypsin hydrolysis	39
5) Absorption, excitation, emission spectra of naphthalimide derivatives	40
6) Absorption, excitation, emission spectra of labeled BSA	41
7) Determination of <i>F/P</i> ratio of labeled BSA	41
4) Mass analyses.....	42
1) ESI-MS analysis of a $2.17 \times 10^2 \mu\text{M}$ solution of coumarins 1 - 5 - 6 in a 1:1:1 molar ratio.....	42
2) ESI-MS analysis of a $5 \times 10^2 \mu\text{M}$ solution of peptide 16-17 in a 1:1 molar ratio	43
3) ESI-MS analysis of a $2.17 \times 10^2 \mu\text{M}$ solution of 28 and 29 in a 1:1 molar ratio.....	44
4) LC -MS analysis of the crude BACE1-mediated hydrolysis (solution of 19 and 20 at $25 \mu\text{M}$).....	45
5) LC -MS analysis of the crude α -Chymotrypsin-mediated hydrolysis (solution of 19 and 20 at $25 \mu\text{M}$).....	49
6) MALDI-TOF analysis of unlabeled and labeled BSA protein.	52
7) MALDI mass spectra of Chymotrypsin and Trypsin digests of modified BSA.	53


1) Copies of ^1H NMR, ^{13}C NMR spectra

Methyl 2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetate 1

^1H NMR spectrum in CDCl_3 (300 MHz)




^{13}C NMR spectrum in CDCl_3 (75 MHz)




2-(7-Methoxy-2-oxo-2H-chromen-4-yl)acetic acid 2

^1H NMR spectrum in $(\text{CD}_3)_2\text{CO}$ (300 MHz)




Methyl 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetate 3

^1H NMR spectrum in $(\text{CD}_3)_2\text{SO}$ (300 MHz)




Methyl 2-(7-(3-bromopropoxy)-2-oxo-2H-chromen-4-yl)-acetate 4

¹H NMR spectrum in CDCl₃ (300 MHz)




¹³C NMR spectrum in CDCl₃ (75 MHz)




(3-((4-(2-methoxy-2-oxoethyl)-2-oxo-2H-chromen-7yl)oxy)propyl)triphenylphosphonium bromide 5

¹H NMR spectrum in CDCl₃ (300 MHz)




¹³C NMR spectrum in CDCl₃ (75 MHz)




3-((4-(2-methoxy-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)-N,N,N-trimethylpropan-1-aminium bromide 6

^1H NMR spectrum in CD_3OD (300 MHz)




^{13}C NMR spectrum in CD_3OD (75 MHz)




(3-((4-(carboxymethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)-triphenylphosphonium bromide 7

¹H NMR spectrum in CD₃OD (300 MHz)




¹³C NMR spectrum in CD₃OD (75 MHz)




2-(7-(3-bromopropoxy)-2-oxo-2H-chromen-4-yl)acetic acid **8**

^1H NMR spectrum in $(\text{CD}_3)_2\text{CO}$ (300 MHz)




^{13}C NMR spectrum in $(\text{CD}_3)_2\text{CO}$ (75 MHz)




2-(7-(3-bromopropoxy)-2-oxo-2H-chromen-4-yl)-N-(prop-2-yn-1-yl)acetamide 9


^1H NMR spectrum in $(\text{CD}_3)_2\text{CO}$ (300 MHz)




^{13}C NMR spectrum in $(\text{CD}_3)_2\text{CO}$ (75 MHz)



(3-((2-oxo-4-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium bromide 10
¹H NMR spectrum in CD₃CN (300 MHz)




¹³C NMR spectrum in CD₃CN (75 MHz)




Tert-butyl (3-(2-(7-(3-bromopropoxy)-2-oxo-2H-chromen-4-yl)acetamido)propyl)carbamate 11

¹H NMR spectrum in CDCl₃ (300 MHz)




¹³C NMR spectrum in CDCl₃ (75 MHz)




tert-butyl (3-(2-(2-oxo-7-(3-(triphenyl-1*l*-phosphanyl)propoxy)-2H-chromen-4-yl)acetamido)propyl)carbamate 12

¹H NMR spectrum in CDCl₃ (300 MHz)




¹³C NMR spectrum in CDCl₃ (75 MHz)




(3-((4-(2-((3-aminopropyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenyl-phosphonium bromide 13

¹H NMR spectrum in CD₃OD (300 MHz)




¹³C NMR spectrum in CD₃OD (75 MHz)




2,5-Dioxopyrrolidin-1-yl 2-iodoacetate

^1H NMR spectrum in $(\text{CD}_3)_2\text{SO}$ (300 MHz)




(3-((4-(2-((3-(2-iodoacetamido)propyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium 2,2,2-trifluoroacetate 14

¹H NMR spectrum in CD₃OD (300 MHz)




¹³C NMR spectrum in CD₃OD (75 MHz)




(3-((4-(2-((3-(6-(5-ethoxy-2-methyloxazol-4-yl)hexanamido)propyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium 2,2,2-trifluoroacetate 15

¹H NMR spectrum in CD₃OD (300 MHz)




¹³C NMR spectrum in CD₃OD (75 MHz)




2,5-dioxopyrrolidin-1-yl 5-azidopentanoate

^1H NMR spectrum in CDCl_3 (300 MHz)




(2,4-dinitrophenyl)glycine

¹H NMR spectrum in CD₃OD (300 MHz)




(3-ammoniopropyl)triphenylphosphonium bromide

^1H NMR spectrum in $(\text{CD}_3)_2\text{SO}$ (300 MHz)




4-Chloro-(N-(2-propyn-1-yl))-1,8-naphthalimide 27

¹H NMR spectrum in CDCl₃ (300 MHz)




2-(prop-2-yn-1-yl)-6-(propylamino)-1H-benzo[de]isoquinoline-1,3(2H)-dione 28

¹H NMR spectrum in CDCl₃ (300 MHz)




¹³C NMR spectrum in CDCl₃ (75 MHz)




(3-((1,3-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)amino)propyl)triphenylphosphonium bromide 29

¹H NMR spectrum in CDCl₃ (300 MHz)



¹³C NMR spectrum in CDCl₃ (75 MHz)




* DMSO residual peak


2) RP-HPLC elution profiles

The following analytical RP-HPLC were performed using the System QC: (Thermo Hypersyl GOLD C18 column, 5 μ m, 2.1 x 100 mm) with ACN and 0.1% aq. TFA as eluents [0% ACN (5 min) followed by linear gradient from 0% to 100% (40 min) of ACN] at a flow rate of 0.25 mL/min.


Methyl 2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetate 1




2-(7-Methoxy-2-oxo-2H-chromen-4-yl)acetic acid 2




(3-((4-(2-methoxy-2-oxoethyl)-2-oxo-2H-chromen-7yl)oxy)-propyl)triphenylphosphonium bromide 5




3-((4-(2-methoxy-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)-N,N,N-trimethylpropan-1-aminium bromide 6




(3-((4-(carboxymethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)-triphenylphosphonium bromide 7




(3-((2-oxo-4-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-2H-chromen-7-yl)oxy)propyl)triphenyl-phosphonium bromide 10




(3-((4-(2-((3-aminopropyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenyl-phosphonium bromide 13




(3-((4-(2-((3-(2-iodoacetamido)propyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium 2,2,2-trifluoroacetate 14




(3-((4-(2-((3-(6-(5-ethoxy-2-methyloxazol-4-yl)hexanamido)propyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium 2,2,2-trifluoroacetate 15




Phosphonium-tagged tetrapeptide 17




(MOCac)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 19




(PPh₃C)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 20




RP-HPLC analysis of a $2.17 \times 10^2 \mu\text{M}$ solution of coumarins 1 - 5 - 6 in a 1:1:1 molar ratio.



2-(prop-2-yn-1-yl)-6-(propylamino)-1H-benzo[de]isoquinoline-1,3(2H)-dione 28




(3-((1,3-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)amino)propyl)triphenylphosphonium bromide 29



3) Spectroscopic data


1) Absorption, excitation, emission spectra of coumarin derivatives

Methyl 2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetate 1




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

2-(7-Methoxy-2-oxo-2H-chromen-4-yl)acetic acid 2




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((4-(2-methoxy-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)-propyl)triphenylphosphonium bromide 5




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

3-((4-(2-methoxy-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)-N,N,N-trimethylpropan-1-aminium bromide 6




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((4-(carboxymethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)-triphenylphosphonium bromide 7




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((2-oxo-4-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium bromide 10




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((4-(2-((3-aminopropyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenyl-phosphonium bromide 13




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((4-(2-((3-(2-iodoacetamido)propyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenyl-phosphonium 2,2,2-trifluoroacetate 14




Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((4-(2-((3-(6-(5-ethoxy-2-methyloxazol-4-yl)hexanamido)propyl)amino)-2-oxoethyl)-2-oxo-2H-chromen-7-yl)oxy)propyl)triphenylphosphonium 2,2,2-trifluoroacetate 15



Absorption (green), excitation (blue, $\lambda_{em} = 390$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.


2) Absorption of the quencher, emission of coumarins 2 and 7 spectra superimposition



Quencher (2,4-dinitrophenyl)glycine absorption (red), coumarin 2 emission (blue, $\lambda_{ex} = 315$ nm), coumarin 7 emission (green, $\lambda_{ex} = 315$ nm), spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

3) Quenching efficiency and fluorescence exaltation of probes 19 and 20 after BACE-1 hydrolysis

(MOCAc)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 19




Emission (λ_{ex} = 328 nm) spectra in acetate buffer (pH 4.48, 0.1 M) at 25 °C.

Quenching Efficiency = 91 %

Fluorescence Exaltation = 11

(PPh₃C)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 20




Emission (λ_{ex} = 328 nm) spectra in acetate buffer (pH 4.48, 0.1 M) at 25 °C.

Quenching Efficiency = 84 %

Fluorescence Exaltation = 6.2

4) Quenching efficiency and fluorescence exaltation of probes 19 and 20 after α -Chymotrypsin hydrolysis

(MOCAC)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 19




Emission (λ_{ex} = 328 nm) spectra in Tris buffer (pH 7.8, 0.1 M Tris + 10 mM $CaCl_2$) at 25 °C.

Quenching Efficiency = 91 %

Fluorescence Exaltation = 10.7

(PPh₃C)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 20





Emission (λ_{ex} = 328 nm) spectra in Tris buffer (pH 7.8, 0.1 M Tris + 10 mM $CaCl_2$) at 25 °C.

Quenching Efficiency = 84 %

Fluorescence Exaltation = 6.3



5) Absorption, excitation, emission spectra of naphthalimide derivatives

2-(prop-2-yn-1-yl)-6-(propylamino)-1H-benzo[de]isoquinoline-1,3(2H)-dione 28




Absorption (green), excitation (blue, $\lambda_{em} = 600$ nm), emission (red, $\lambda_{ex} = 410$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

(3-((1,3-dioxo-2-(prop-2-yn-1-yl)-2,3-dihydro-1H-benzo[de]isoquinolin-6-yl)amino)propyl)triphenylphosphonium bromide 29




Absorption (green), excitation (blue, $\lambda_{em} = 600$ nm), emission (red, $\lambda_{ex} = 410$ nm) spectra in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

6) Absorption, excitation, emission spectra of labeled BSA



Absorption (green), excitation (blue, $\lambda_{em} = 425$ nm), emission (red, $\lambda_{ex} = 315$ nm) spectra in milliQ water at 25 °C.

7) Determination of F/P ratio of labeled BSA



Absorption spectra of unlabeled BSA (blue), Absorption spectra of **14** (green), absorption spectra of labeled BSA (red) in PBS (pH 7.4, 0.1 M phosphate + 0.15 M NaCl) at 25 °C.

The degree of labeling of the BSA protein, *i.e.* the fluorophore:protein (F/P) molar ratios, were estimated from the relative intensities of protein and dye absorption, according to the following equation:


$$\frac{F}{P} = \frac{C_f}{C_p} = \frac{\epsilon_{P,280} A_{326}}{\epsilon_{F,326} (A_{280} - (f \times A_{326}))}$$

The molar absorption coefficient of the BSA protein $\epsilon_{p,280}$ was determined to be $45551 \text{ M}^{-1} \text{ cm}^{-1}$ at 280 nm in milliQ water at 25 °C. The molar absorption coefficient of **14** $\epsilon_{F,326}$ was determined to be $12252 \text{ M}^{-1} \text{ cm}^{-1}$ at 326 nm in milliQ water at 25 °C. The correction factor f equal to the ration of fluorophore absorbance at 280 and 326 nm was calculated to be 0.3469.

For labeled BSA protein, $A_{280} = 0.4077$ and $A_{326} = 0.1186$; allowing $F/P = 1.2$.


4) Mass spectrometry analyses

1) ESI-MS analysis of a $2.17 \times 10^2 \mu\text{M}$ solution of coumarins 1 - 5 -6 in a 1:1:1 molar ratio.




ESI-MS parameters : ESI⁺; Full scan mode; Sheath Gas Flow Rate (arb): 20; Aux/Sweep Gas Flow Rate (arb): 0; I Spray Voltage (kV) I: 5.4; Capillary Temp (°C): 220; Capillary Voltage (V): 36; Tube Lens Offset (V): 50; Injection flow rate (ml/min): 0.25

2) ESI-MS analysis of a $5 \times 10^2 \mu\text{M}$ solution of peptide 16-17 in a 1:1 molar ratio.



ESI-MS parameters : ESI⁺; Full scan mode; Sheath Gas Flow Rate (arb): 20; Aux/Sweep Gas Flow Rate (arb): 0; I Spray Voltage (kV) I: 5.4; Capillary Temp (°C): 220; Capillary Voltage (V): 36; Tube Lens Offset (V): 50; Injection flow rate (ml/min): 0.25

3) ESI-MS analysis of a $2.17 \times 10^2 \mu\text{M}$ solution of 28 and 29 in a 1:1 molar ratio.




ESI-MS parameters (HCT Ultra ETD II mass spectrometer): ESI⁺; Full scan mode; Nebulizer Gas Flow Rate (Psi): 20; Dry Gas Flow Rate (L/min.): 5; Dry Temp (°C): 300; Capillary Voltage (V): -3000; Skimmer (V): 40; Injection flow rate (ml/min): 0.25.


4) LC-MS analysis of the crude BACE1-mediated hydrolysis (solution of 19 and 20 at 25 μM).

(MOCAc)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 19


Total ion current (TIC) chromatogram:




ESI mass spectrum of the compound 22 ($t_R = 18.8$ min).



ESI mass spectrum of the compound **21** ($t_R = 22.7$ min).




ESI mass spectrum of the compound **19** ($t_R = 23.3$ min).




(PPh₃C)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 20


Total ion current (TIC) chromatogram:




ESI mass spectrum of the compound **22**. ($t_R = 18.8$ min)



ESI mass spectrum of the compound **23** ($t_R = 24.4$ min).




ESI mass spectrum of the compound **20** ($t_R = 23.9$ min).




5) LC -MS analysis of the crude α -Chymotrypsin-mediated hydrolysis (solution of 19 and 20 at 25 μ M).

(MOCAc)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 19


Total ion current (TIC) chromatogram:



ESI mass spectrum of the compound 25 ($t_R = 14.6$ min).




ESI mass spectrum of the compound **24** ($t_R = 24.2$ min).




(PPh₃C)-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys-(DNPA)-Arg-Arg 20


Total ion current (TIC) chromatogram:




ESI mass spectrum of the compound **25** ($t_R = 14.6$ min).



ESI mass spectrum of the compound **26** ($t_R = 25.0$ min).




6) MALDI-TOF analysis of unlabeled and labeled BSA protein.




MALDI-TOF analysis of unlabeled BSA (red) and labeled (black) protein.

7) MALDI mass spectra of Chymotrypsin and Trypsin digests of modified BSA.



a) MALDI mass spectrum of chymotrypsin digest of modified BSA (CHCA matrix - C_n : chymotryptic peptides.) The enlargement of the *m/z* 1950-2010 range showing the chymotryptic peptide at *m/z* 1961.82 containing the fluorophore group is on the top right of the figure. **b)** MALDI-MS/MS spectrum of the precursor ion at *m/z* 1961.82. The fragment ions at *m/z* 303.1, 505.3, 579.4 and 653.5 are specific of the fluorophore group. **c)** MALDI mass spectrum of trypsin digest of modified BSA (CHCA matrix - T_n : tryptic peptides.) The enlargement of the *m/z* 3040-3070 range showing the tryptic peptide at *m/z* 3053.67 containing the fluorophore group is on the top right of the figure. **d)** MALDI-MS/MS spectrum of the precursor ion at *m/z* 3053.67. The fragment ions at *m/z* 302.1, 504.6, 578.9 and 653.0 are specific of the fluorophore group.



Fragment ions of the fluorophore group.